Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) have earned a consensus rating of “Moderate Buy” from the seven analysts that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $21.40.

Several equities research analysts have recently commented on the company. Canaccord Genuity Group lowered their target price on Stoke Therapeutics from $21.00 to $20.00 and set a “buy” rating for the company in a research note on Tuesday, May 7th. Wedbush reiterated an “outperform” rating and issued a $17.00 price objective on shares of Stoke Therapeutics in a research report on Thursday, July 11th. HC Wainwright restated a “buy” rating and set a $35.00 target price on shares of Stoke Therapeutics in a research report on Tuesday, May 7th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $22.00 price target on shares of Stoke Therapeutics in a research report on Thursday, August 8th.

Stoke Therapeutics Stock Up 4.7 %

Shares of NASDAQ:STOK opened at $14.55 on Tuesday. The firm has a market cap of $766.06 million, a P/E ratio of -6.04 and a beta of 0.87. Stoke Therapeutics has a 12 month low of $3.35 and a 12 month high of $17.58. The company’s 50-day moving average price is $14.07 and its two-hundred day moving average price is $12.39.

Stoke Therapeutics (NASDAQ:STOK) last announced its earnings results on Wednesday, August 7th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.11. Stoke Therapeutics had a negative net margin of 683.35% and a negative return on equity of 57.89%. The company had revenue of $4.83 million for the quarter, compared to analyst estimates of $3.33 million. As a group, equities analysts predict that Stoke Therapeutics will post -2.18 earnings per share for the current fiscal year.

Insider Transactions at Stoke Therapeutics

In other Stoke Therapeutics news, insider Barry Ticho sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $13.75, for a total value of $137,500.00. Following the completion of the sale, the insider now owns 2,485 shares of the company’s stock, valued at $34,168.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 11.30% of the company’s stock.

Institutional Trading of Stoke Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Lynx1 Capital Management LP increased its stake in Stoke Therapeutics by 40.3% during the 2nd quarter. Lynx1 Capital Management LP now owns 5,185,191 shares of the company’s stock worth $70,052,000 after purchasing an additional 1,488,371 shares in the last quarter. The Manufacturers Life Insurance Company increased its position in shares of Stoke Therapeutics by 16.7% during the second quarter. The Manufacturers Life Insurance Company now owns 13,964 shares of the company’s stock worth $189,000 after acquiring an additional 1,994 shares in the last quarter. Millennium Management LLC increased its position in shares of Stoke Therapeutics by 528.6% during the second quarter. Millennium Management LLC now owns 289,067 shares of the company’s stock worth $3,905,000 after acquiring an additional 243,083 shares in the last quarter. Marshall Wace LLP raised its holdings in shares of Stoke Therapeutics by 550.1% during the second quarter. Marshall Wace LLP now owns 1,161,037 shares of the company’s stock worth $15,686,000 after acquiring an additional 982,451 shares during the period. Finally, Logos Global Management LP bought a new stake in Stoke Therapeutics in the 2nd quarter valued at $14,186,000.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.